CoChat

Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

Open access

The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.

Abstract

Background: Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to explore complementary therapeutic approaches. Genome-wide association studies identified robust associations between AD and several AD risk genes related to immune response, including but not restricted to CD33 and TREM2 . Here, we critically reviewed the current knowledge on candidate neuroinflammatory biomarkers and their role in characterizing the pathophysiology of AD. Main body: Neuroinflammation is recognized to be a crucial and contributing component of AD pathogenesis. The fact that neuroinflammation is most likely present from earliest pre-stages of AD and co-occurs with the deposition of Aβ reinforces the need to precisely define the sequence and nature of neuroinflammatory events. Numerous clinical trials involving anti-inflammatory drugs previously yielded unfavorable outcomes in early and mild-to-moderate AD. Although the reasons behind these failures remain unclear, these may include the time and the target selected for intervention. Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain. While the initial activation of glial cells counteracts early brain Aβ deposition, the downregulation in the functional state of microglia occurs at more advanced disease stages. To address this issue, personalized neuroinflammatory modulation therapy is required. The emergence of reliable blood-based neuroinflammatory biomarkers, particularly glial fibrillary acidic protein, a marker of reactive astrocytes, may facilitate the classification of AD patients based on the ATI(N) biomarker framework. This expands upon the traditional classification of Aβ (“A”), tau (“T”), and neurodegeneration (“N”), by incorporating a novel inflammatory component (“I”). Conclusions: The present review outlines the current knowledge on potential neuroinflammatory biomarkers and, importantly, emphasizes the role of longitudinal analyses, which are needed to accurately monitor the dynamics of cerebral inflammation. Such a precise information on time and place will be required before anti-inflammatory therapeutic interventions can be considered for clinical evaluation. We propose that an effective anti-neuroinflammatory therapy should specifically target microglia and astrocytes, while considering the individual ATI(N) status of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-024-03163-y

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A Pathological interactions between glia and neurons in AD. Amyloid-beta species can be recognized by and activate microglia, which contribute to activate astrocytes. These cells release pro-inflammatory cytokines and chemokines and lose their homeostatic functions, leading to disruption of the BBB and neuronal damage. Deficit of anti-inflammatory cytokines (e.g. TGF-β1) also contributes to microglial activation and synaptic dysfunction. Disease associated microglia can also directly eliminate synaptic structures. B “Eat-me” signals and the quad-partite synapse in AD. Neuronal eat-me signals are recognized by several phagocytic receptors on both astrocytes and microglia. Some of these signals include milk fat globule-EGF factor 8 protein (MFGE8) and Protein S, both bound to exposed phosphatidylserine, and complement component 3 (C3) and 1q (C1q). Microglia use as cell-surface receptors the complement receptor 3 (CR3), vitronectin receptor (VNR), MER receptor tyrosine kinase (MERTK) and triggering receptor expressed on myeloid cells 2 (TREM2) among others. Astrocytes may also contribute to synaptic engulfment via the binding of C1q to multiple EGF-like domains 10 (MEGF10). Metabotropic glutamate receptor 5 (mGluR5) may also induce synaptotoxicity via calcium dysregulation and complement activation, making the synapses a target for removal by astrocytes and microglia. Interactions between α7 nicotinic acetylcholine receptors (α7nAChRs) and soluble amyloid-β (Aβ) can also contribute to reactive astrogliosis and neuronal death, through the excessive release of glutamate from astrocytes in a Ca2 + -dependent manner. α7nAChRs α7 nicotinic acetylcholine receptors, Aβ amyloid-β, AD Alzheimer disease, BBB blood–brain barrier, C1q complement component, C3 complement component 3, CR3 complement receptor 3 (CR3), IL interleukin, MEGF10 multiple EGF-like domains 10, MERTK MER, receptor tyrosine kinase, MFGE8 milk fat globule-EGF factor 8 protein, mGluR5 Metabotropic glutamate receptor 5, TGF-β1 transforming growth factor-beta 1, TNF tumor necrosis factor, TREM2 triggering receptor expressed on myeloid cells 2, VNR vitronectin receptor
Fig. 1 A Pathological interactions between glia and neurons in AD. Amyloid-beta species can be recognized by and activate microglia, which contribute to activate astrocytes. These cells release pro-inflammatory cytokines and chemokines and lose their homeostatic functions, leading to disruption of the BBB and neuronal damage. Deficit of anti-inflammatory cytokines (e.g. TGF-β1) also contributes to microglial activation and synaptic dysfunction. Disease associated microglia can also directly eliminate synaptic structures. B “Eat-me” signals and the quad-partite synapse in AD. Neuronal eat-me signals are recognized by several phagocytic receptors on both astrocytes and microglia. Some of these signals include milk fat globule-EGF factor 8 protein (MFGE8) and Protein S, both bound to exposed phosphatidylserine, and complement component 3 (C3) and 1q (C1q). Microglia use as cell-surface receptors the complement receptor 3 (CR3), vitronectin receptor (VNR), MER receptor tyrosine kinase (MERTK) and triggering receptor expressed on myeloid cells 2 (TREM2) among others. Astrocytes may also contribute to synaptic engulfment via the binding of C1q to multiple EGF-like domains 10 (MEGF10). Metabotropic glutamate receptor 5 (mGluR5) may also induce synaptotoxicity via calcium dysregulation and complement activation, making the synapses a target for removal by astrocytes and microglia. Interactions between α7 nicotinic acetylcholine receptors (α7nAChRs) and soluble amyloid-β (Aβ) can also contribute to reactive astrogliosis and neuronal death, through the excessive release of glutamate from astrocytes in a Ca2 + -dependent manner. α7nAChRs α7 nicotinic acetylcholine receptors, Aβ amyloid-β, AD Alzheimer disease, BBB blood–brain barrier, C1q complement component, C3 complement component 3, CR3 complement receptor 3 (CR3), IL interleukin, MEGF10 multiple EGF-like domains 10, MERTK MER, receptor tyrosine kinase, MFGE8 milk fat globule-EGF factor 8 protein, mGluR5 Metabotropic glutamate receptor 5, TGF-β1 transforming growth factor-beta 1, TNF tumor necrosis factor, TREM2 triggering receptor expressed on myeloid cells 2, VNR vitronectin receptorCC BY · PubMed Central
Fig. 2 Presently ongoing clinical trials in AD by mechanism of action of the tested agents. Twenty-five trials are testing anti-neuroinflammatory agents. AD Alzheimer disease, APOE Apolipoprotein E. Modified from Cummings et al. Alzheimers Dement (N Y). 2024 [12]
Fig. 2 Presently ongoing clinical trials in AD by mechanism of action of the tested agents. Twenty-five trials are testing anti-neuroinflammatory agents. AD Alzheimer disease, APOE Apolipoprotein E. Modified from Cummings et al. Alzheimers Dement (N Y). 2024 [12]CC BY · PubMed Central
Fig. 3 Hypothetical time course profiles of main fluid neuroinflammatory biomarkers (GFAP, sTREM2, and YKL-40) across the AD continuum. The biomarker levels presented in the graph are referred to their normal range and should not be compared with each other. AD Alzheimer disease, CSF cerebrospinal fluid, GFAP glial fibrillary acidic protein, MCI mild cognitive impairment, sTREM2 soluble triggering receptor expressed on myeloid cells 2, YKL-40 chitinase-3-like protein 1
Fig. 3 Hypothetical time course profiles of main fluid neuroinflammatory biomarkers (GFAP, sTREM2, and YKL-40) across the AD continuum. The biomarker levels presented in the graph are referred to their normal range and should not be compared with each other. AD Alzheimer disease, CSF cerebrospinal fluid, GFAP glial fibrillary acidic protein, MCI mild cognitive impairment, sTREM2 soluble triggering receptor expressed on myeloid cells 2, YKL-40 chitinase-3-like protein 1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Neurotoxic reactive astrocytes are induced by activated microglia

    Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · cited 2×

    “Furthermore, considering that neurotoxic reactive astrocytes are stimulated by activated microglia [117], the availability of a biomarker for activated microglia becomes essential in identifying individuals who are at a higher risk of developing AD.”
    Background
  • Neuroinflammation in Alzheimer's disease

    Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226

    Self-citation
  • Lecanemab in early Alzheimer's disease

    van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · cited 1×

    “Accordingly, blood GFAP concentrations have already been successfully employed as a biomarker in clinical trials evaluating anti-Aβ monoclonal antibodies, such as lecanemab [148] and donanemab [149].”
    Method
  • A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease

    Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 1×

    “The binding of TREM2 to ligands, including anionic lipids, lipoproteins, and Aβ, initiates downstream signaling cascades that promote microglial survival, proliferation, chemotaxis, and phagocytosis [43, 44].”
    Background
  • TREM2 Variants in Alzheimer's Disease

    Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020

  • Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

    Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · cited 1×

    “A recent phase III clinical trial evaluated the efficacy of donanemab, a monoclonal antibody targeting a pyroglutamate form of Aβ, in individuals with prodromal AD and mild dementia due to AD [5].”
    Background
  • Variant of TREM2 Associated with the Risk of Alzheimer's Disease

    Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×

    “The significance of TREM2 in the pathogenesis of AD was underscored by the discovery of a specific heterozygous mutation, R47H, which substantially elevates the risk of developing LOAD [45, 46].”
    Background
  • Donanemab in Early Alzheimer’s Disease

    Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1×

    “…more recently, with donanemab—a potent anti-Aβ(p3-42) monoclonal antibody—exclusively enrolled patients who, as confirmed by [ 18 F]flortaucipir-PET scans, exhibited pathologic tau deposition (> 1.10 SUVR), but with quantitative tau levels below a specific upper threshold (1.46 SUVR) [151].”
    BackgroundInfluential
  • TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease

    Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263

  • A Meta-Analysis of Cytokines in Alzheimer's Disease

    Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108 · cited 1×

    “…which included 54 studies measuring cytokine concentrations (40 in peripheral blood and 14 in the CSF), patients with AD exhibited higher concentrations of IL-6, TNF-α, IL-1β, TGF-β, IL-12, and IL-18 in peripheral blood, and elevated levels of TGF-β in CSF, compared to healthy controls [141].”
    Background

Show all 180 references

Cited by

See all 84

Metadata

Authors
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., Malaguti, M., Melchiorri, D., Santos-Lozano, A., Imbimbo, C., Heneka, M. T., & Caraci, F.
Affiliations
  • Universidad Europea Miguel de Cervantes (ES)
  • Chiesi (Italy) (IT)
  • University of Catania (IT)
  • University of Bologna (IT)
  • Sapienza University of Rome (IT)
  • University of Pavia (IT)
  • University of Luxembourg (LU)
Corresponding author
  • Lista, Simone
  • Heneka, Michael T.
  • Caraci, Filippo
Venue
Journal of Neuroinflammation
Published
2024-07-30
Volume
21
Issue
1
Pages
187-187
ISSN
1742-2094 (ISSN-L)
OpenAlex
W4401107572
Cited by
81
References
179
Citations by year
2026: 30 · 2025: 46 · 2024: 5
FWCI
4.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
Funders
Ministerio de Ciencia e Innovación (FPU19/02117)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, neuroinflammation, neuroinflammatory biomarkers, microglia, astrocytes, glial fibrillary acidic protein, anti-inflammatory therapy, anti-amyloid beta monoclonal antibody, CD33, TREM2, blood-based biomarkers, disease staging, personalized treatment, longitudinal biomarker dynamics
MeSH terms
Neuroinflammatory Diseases, Alzheimer Disease, Animals, Humans, Biomarkers, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches? https://app.cochat.ai/papers/10.1186/s12974-024-03163-y
The paper
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., Malaguti, M., Melchiorri, D., Santos-Lozano, A., Imbimbo, C., Heneka, M. T., & Caraci, F. (2024). Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches? Journal of Neuroinflammation. https://doi.org/10.1186/s12974-024-03163-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.